Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to assess the preliminary efficacy, safety, tolerability, PK, and PD of Daxdilimab in participants with moderate to severe AA, with ≥50% and ≤95% total scalp hair loss as defined by the SALT score at Screening and Day 1.
Approximately 30 participants will be enrolled to receive daxdilimab administered subcutaneously over 32 weeks. The maximum trial duration per participant is approximately 52 weeks, including up to 30 days for the screening period, 32 weeks for the open-label treatment period where participants will receive daxdilimab and approximately 16 weeks for the follow-up period. Safety evaluations will be performed regularly throughout the course of the study.
Study acquired from Horizon in 2024.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Daxdilimab | Experimental | Nine sets of Daxdilimab injections over a total of 32 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Daxdilimab | Biological | Daxdilimab will be administered subcutaneously as two injections for each dose. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percent Change From Baseline in SALT Score at Week 24 | The SALT score determined the degree of hair loss based on the percentage of scalp surface area involved on the top, back, and each side of the scalp for AA. The Investigator determined the percent scalp hair loss in a given quadrant, multiplied this by the total scalp area delineated by that quadrant, and summed the resultant numbers for each quadrant to give the total percent scalp hair loss with a range of 0-100. Higher scores indicated more severe AA symptoms. A decrease in SALT score from baseline indicated a reduction in AA symptoms. Baseline indicates last non-missing valid observation prior to the first dose of daxdilimab. | Baseline to Week 24 |
| Measure | Description | Time Frame |
|---|---|---|
| Percent Change From Baseline in SALT Score at Weeks 12, 16, 20, 28, 32, and 36 | The SALT score determined the degree of hair loss based on the percentage of scalp surface area involved on the top, back, and each side of the scalp for AA. The Investigator determined the percent scalp hair loss in a given quadrant, multiplied this by the total scalp area delineated by that quadrant, and summed the resultant numbers for each quadrant to give the total percent scalp hair loss with a range of 0-100. Higher scores indicated more severe AA symptoms. A decrease in SALT score from baseline indicated a reduction in AA symptoms. Baseline indicates last non-missing valid observation prior to the first dose of daxdilimab. |
Not provided
Inclusion Criteria:
Willing and able to give informed consent.
Willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the trial.
Adult men or women 18 to 65 years of age.
Willing to keep the same hair style and color (eg, hair products, process, and timing for hair appointments) for the duration of the trial.
Clinical diagnosis of moderate-to-severe AA - defined as meeting the following criteria:
Exclusion Criteria:
Individuals involved in the conduct of the trial, their employees, or immediate family members of such individuals.
Any clinically significant medical condition or physical/laboratory/ECG/vital signs abnormality that would, in the opinion of the investigator, put the participant at undue risk or interfere with the evaluation of the IP or interpretation of trial results.
History of allergy, hypersensitivity reaction, or anaphylaxis to any component of the IP or to a previous monoclonal antibody (mAb) or human immunoglobulin (Ig) therapy.
Participant has had excessive sun exposure, is planning a trip to a sunny climate, or has used tanning booths within 4 weeks prior to Day 1 or is not willing to minimize natural and artificial sunlight exposure during the trial. Use of sunscreen products and protective apparel are recommended when sun exposure cannot be avoided.
Known history of a primary immunodeficiency or an underlying condition such as known human immunodeficiency virus (HIV) infection, a positive result for HIV infection, splenectomy, or any underlying condition that in the opinion of the investigator significantly predisposes the participant to infection.
Confirmed positive test for hepatitis B serology defined as:
Positive test for hepatitis C virus antibody.
Active tuberculosis (TB), or a positive TB test at Screening. Participant will be evaluated for latent TB infection with a purified protein derivative (PPD) test or a QuantiFERON-TB Gold test. Participants who demonstrate evidence of latent TB infection (either PPD ≥5 mm of induration or positive QuantiFERON-TB Gold test, irrespective of bacille Calmette-Guérin vaccination status will not be allowed to participate in the trial, unless documented history of appropriate treatment for active or latent TB. Participants with an indeterminate test result can repeat the test, but if the repeat test is also indeterminate, they are excluded.
Any severe herpes virus family infection (including Epstein-Barr virus, cytomegalovirus [CMV]) at any time prior to Day 1, including, but not limited to, disseminated herpes, herpes encephalitis, recent recurrent herpes zoster (defined as 2 episodes within the last 2 years), or ophthalmic herpes.
Any herpes zoster, CMV, or Epstein-Barr virus infection that was not completely resolved 12 weeks prior to Day 1.
Any of the following within 30 days prior to signing the ICF and though Day 1:
Opportunistic infection requiring hospitalization or parenteral antimicrobial treatment within 2 years prior to Day 1.
Any acute illness or evidence of clinically significant active infection, such as fever ≥ 38.0°C (≥ 100.5°F) on Day 1.
History of clinically significant cardiac disease including unstable angina; myocardial infarction within 6 months prior to Day 1; congestive heart failure; arrhythmia requiring active therapy, except for clinically insignificant extra systoles, or minor conduction abnormalities; or presence of clinically significant abnormality on ECG if, in the opinion of the investigator, it would increase the risk of trial participation.
History of cancer or lymphoproliferative disease within 5 years prior to Day 1, except as follows:
Active forms of other inflammatory skin disease(s) or evidence of other skin conditions (eg, psoriasis, seborrheic dermatitis, lupus) at the time of the Screening and through Day 1, that in the opinion of the investigator might interfere with evaluation of AA and the assessment of the activity measures.
Presence of another form of alopecia (except for androgenic alopecia).
History of male or female pattern hair loss > Hamilton stage III or > Ludwig stage II.
History or presence of hair transplants.
History or presence of micropigmentation of the scalp (Note: microblading of the eyebrows is permitted).
Use of steroids (systemic and intralesional), anthralin, squaric acid, diphenylcycloprophenone (DPCP), dinitrochlorobenzene (DCNB), protopic, minoxidil, or any other medication which in the opinion of the investigator may affect hair regrowth within 4 weeks of Day 1 visit. Note: Intranasal and inhaled corticosteroids are allowed, eye and ear drops containing corticosteroids are also allowed.
Use of platelet-rich plasma injections in the last 12 weeks prior to Day 1.
Topical medicated treatment that could affect AA including, but not limited to, topical corticosteroids, calcineurin inhibitors, antimicrobials, medical devices within 2 weeks of Day 1 visit. Note: Topical corticosteroids are permitted outside of the scalp, eyebrows, and eyelids.
Participants who have had previous treatment with any biologic B-cell-depleting therapy (eg, rituximab, ocrelizumab, or ofatumumab) or other B-cell targeting therapy (eg, belimumab) within 12 months before Day 1.
Participants who have received previous treatment with pDC inhibiting therapies (eg, anti-ILT7, anti-blood dendritic cell antigen 2 [BDCA2]).
Inadequate response to adequate trial of oral Janus Kinase (JAK) inhibitors. Previous exposure to topical JAK inhibitors is acceptable, regardless of response.
Any biologic or conventional disease-modifying antirheumatic drugs (DMARD), immunosuppressant (eg, cyclosporine, methotrexate, or azathioprine), JAK-inhibitors, interferon (IFN) blocking therapies, or antiproliferative agents, if last dose was taken: a. within 8 weeks prior to Day 1 or b. drug-specific 5 half-lives elimination period (if longer than 8 weeks).
Participant has received any marketed or investigational biological agent within 12 weeks or 5 half-lives (whichever is longer) prior to Day 1.
Currently receiving a nonbiological IP or device or has received one within 4 weeks prior to Day 1 or within 5 published half-lives, whichever is longer.
Participant has received any ultraviolet (UV)-B phototherapy (including tanning beds), has had psoralen-UV-A (PUVA) treatment, or excimer laser within 4 weeks prior to Day 1.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| MD | Amgen | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Burke Pharmaceutical Research | Hot Springs | Arkansas | 71913 | United States | ||
| First OC Dermatology Research, Inc. |
Not provided
| Label | URL |
|---|---|
| AmgenTrials clinical trials website | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Of the 55 participants who were screened for enrolment in the trial, 25 were screen failures. A total of 30 participants were enrolled and received daxdilimab.
A total of 30 participants were enrolled at 5 trial centers located in the United States and 7 trial centers in Canada between 27 April 2022 and 26 January 2024.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Daxdilimab 300 mg | Participants received 300 mg daxdilimab as two subcutaneous (SC) injections every 4 weeks (Q4W) for 32 weeks. Participants were followed-up until Week 48. |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Safety Analysis Set: Included all participants who received any dose of daxdilimab.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Daxdilimab 300 mg | Participants received 300 mg daxdilimab as two subcutaneous (SC) injections every 4 weeks (Q4W) for 32 weeks. Participants were followed-up until Week 48. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percent Change From Baseline in SALT Score at Week 24 | The SALT score determined the degree of hair loss based on the percentage of scalp surface area involved on the top, back, and each side of the scalp for AA. The Investigator determined the percent scalp hair loss in a given quadrant, multiplied this by the total scalp area delineated by that quadrant, and summed the resultant numbers for each quadrant to give the total percent scalp hair loss with a range of 0-100. Higher scores indicated more severe AA symptoms. A decrease in SALT score from baseline indicated a reduction in AA symptoms. Baseline indicates last non-missing valid observation prior to the first dose of daxdilimab. | Safety Analysis Set: Included all participants who received any dose of daxdilimab. | Posted | Mean | Standard Deviation | percent change in score on a scale | Baseline to Week 24 |
|
Day 1 to Week 48
All-cause mortality is reported for all participants enrolled in the study. Serious adverse events and other adverse events are reported for all participants who received at least one dose of daxdilimab.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Daxdilimab 300 mg | Participants received 300 mg daxdilimab as two subcutaneous (SC) injections every 4 weeks (Q4W) for 32 weeks. Participants were followed-up until Week 48. |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Abdominal pain | Gastrointestinal disorders | MedDRA 24.1 | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Study Director | Amgen Inc. | 866-572-6436 | medinfo@amgen.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Jan 7, 2022 | Dec 12, 2024 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Apr 18, 2022 | Dec 12, 2024 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D000506 | Alopecia Areata |
| ID | Term |
|---|---|
| D000505 | Alopecia |
| D007039 | Hypotrichosis |
| D006201 | Hair Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Baseline to Weeks 12, 16, 20, 28, 32, and 36 |
| Percentage of Participants Who Achieved a ≥ 50% Reduction in SALT Score From Baseline at Weeks 12, 16, 20, 24, 28, 32, and 36 | The SALT score determined the degree of hair loss based on the percentage of scalp surface area involved on the top, back, and each side of the scalp for AA. The Investigator determined the percent scalp hair loss in a given quadrant, multiplied this by the total scalp area delineated by that quadrant, and summed the resultant numbers for each quadrant to give the total percent scalp hair loss with a range of 0-100. Higher scores indicated more severe AA symptoms. A decrease in SALT score from baseline indicated a reduction in AA symptoms. Baseline indicates last non-missing valid observation prior to the first dose of daxdilimab. | Baseline to Weeks 12, 16, 20, 24, 28, 32, and 36 |
| Percentage of Participants Who Had an Absolute SALT Score ≤ 10 at Weeks 12, 16, 20, 24, 28, 32, and 36 | The SALT score determined the degree of hair loss based on the percentage of scalp surface area involved on the top, back, and each side of the scalp for AA. The Investigator determined the percent scalp hair loss in a given quadrant, multiplied this by the total scalp area delineated by that quadrant, and summed the resultant numbers for each quadrant to give the total percent scalp hair loss with a range of 0-100. Higher scores indicated more severe AA symptoms. Baseline indicates last non-missing valid observation prior to the first dose of daxdilimab. | Weeks 12, 16, 20, 24, 28, 32, and 36 |
| Percentage of Participants Who Had an Absolute SALT Score ≤ 20 at Weeks 12, 16, 20, 24, 28, 32, and 36 | The SALT score determined the degree of hair loss based on the percentage of scalp surface area involved on the top, back, and each side of the scalp for AA. The Investigator determined the percent scalp hair loss in a given quadrant, multiplied this by the total scalp area delineated by that quadrant, and summed the resultant numbers for each quadrant to give the total percent scalp hair loss with a range of 0-100. Higher scores indicated more severe AA symptoms. Baseline indicates last non-missing valid observation prior to the first dose of daxdilimab. | Weeks 12, 16, 20, 24, 28, 32, and 36 |
| Percentage of Participants Who Had an Absolute SALT Score ≤ 30 at Weeks 12, 16, 20, 24, 28, 32, and 36 | The SALT score determined the degree of hair loss based on the percentage of scalp surface area involved on the top, back, and each side of the scalp for AA. The Investigator determined the percent scalp hair loss in a given quadrant, multiplied this by the total scalp area delineated by that quadrant, and summed the resultant numbers for each quadrant to give the total percent scalp hair loss with a range of 0-100. Higher scores indicated more severe AA symptoms. Baseline indicates last non-missing valid observation prior to the first dose of daxdilimab. | Weeks 12, 16, 20, 24, 28, 32, and 36 |
| Percentage of Participants Who Had an Absolute SALT Score ≤ 50 at Weeks 12, 16, 20, 24, 28, 32, and 36 | The SALT score determined the degree of hair loss based on the percentage of scalp surface area involved on the top, back, and each side of the scalp for AA. The Investigator determined the percent scalp hair loss in a given quadrant, multiplied this by the total scalp area delineated by that quadrant, and summed the resultant numbers for each quadrant to give the total percent scalp hair loss with a range of 0-100. Higher scores indicated more severe AA symptoms. Baseline indicates last non-missing valid observation prior to the first dose of daxdilimab. | Weeks 12, 16, 20, 24, 28, 32, and 36 |
| Percent Change From Baseline in SALT Score at Weeks 40, 44, and 48 | The SALT score determined the degree of hair loss based on the percentage of scalp surface area involved on the top, back, and each side of the scalp for AA. The Investigator determined the percent scalp hair loss in a given quadrant, multiplied this by the total scalp area delineated by that quadrant, and summed the resultant numbers for each quadrant to give the total percent scalp hair loss with a range of 0-100. Higher scores indicated more severe AA symptoms. A decrease in SALT score from baseline indicated a reduction in AA symptoms. Baseline indicates last non-missing valid observation prior to the first dose of daxdilimab. | Baseline to Weeks 40, 44, and 48 |
| Percentage of Participants Who Achieved a ≥ 50% Reduction in SALT Score From Baseline at Weeks 40, 44, and 48 | The SALT score determined the degree of hair loss based on the percentage of scalp surface area involved on the top, back, and each side of the scalp for AA. The Investigator determined the percent scalp hair loss in a given quadrant, multiplied this by the total scalp area delineated by that quadrant, and summed the resultant numbers for each quadrant to give the total percent scalp hair loss with a range of 0-100. Higher scores indicated more severe AA symptoms. A decrease in SALT score from baseline indicated a reduction in AA symptoms. Baseline indicates last non-missing valid observation prior to the first dose of daxdilimab. | Baseline to Weeks 40, 44, and 48 |
| Percentage of Participants Who Had an Absolute SALT Score ≤ 10 at Weeks 40, 44 and 48 | The SALT score determined the degree of hair loss based on the percentage of scalp surface area involved on the top, back, and each side of the scalp for AA. The Investigator determined the percent scalp hair loss in a given quadrant, multiplied this by the total scalp area delineated by that quadrant, and summed the resultant numbers for each quadrant to give the total percent scalp hair loss with a range of 0-100. Higher scores indicated more severe AA symptoms. Baseline indicates last non-missing valid observation prior to the first dose of daxdilimab. | Weeks 40, 44 and 48 |
| Percentage of Participants Who Had an Absolute SALT Score ≤ 20 at Weeks 40, 44 and 48 | The SALT score determined the degree of hair loss based on the percentage of scalp surface area involved on the top, back, and each side of the scalp for AA. The Investigator determined the percent scalp hair loss in a given quadrant, multiplied this by the total scalp area delineated by that quadrant, and summed the resultant numbers for each quadrant to give the total percent scalp hair loss with a range of 0-100. Higher scores indicated more severe AA symptoms. Baseline indicates last non-missing valid observation prior to the first dose of daxdilimab. | Weeks 40, 44 and 48 |
| Percentage of Participants Who Had an Absolute SALT Score ≤ 30 at Weeks 40, 44 and 48 | The SALT score determined the degree of hair loss based on the percentage of scalp surface area involved on the top, back, and each side of the scalp for AA. The Investigator determined the percent scalp hair loss in a given quadrant, multiplied this by the total scalp area delineated by that quadrant, and summed the resultant numbers for each quadrant to give the total percent scalp hair loss with a range of 0-100. Higher scores indicated more severe AA symptoms. Baseline indicates last non-missing valid observation prior to the first dose of daxdilimab. | Weeks 40, 44 and 48 |
| Percentage of Participants Who Had an Absolute SALT Score ≤ 50 at Weeks 40, 44 and 48 | The SALT score determined the degree of hair loss based on the percentage of scalp surface area involved on the top, back, and each side of the scalp for AA. The Investigator determined the percent scalp hair loss in a given quadrant, multiplied this by the total scalp area delineated by that quadrant, and summed the resultant numbers for each quadrant to give the total percent scalp hair loss with a range of 0-100. Higher scores indicated more severe AA symptoms. Baseline indicates last non-missing valid observation prior to the first dose of daxdilimab. | Weeks 40, 44 and 48 |
| Serum Concentration of Daxdilimab | Blood samples were collected at the visits and time points specified. All post-baseline concentrations below the limit of quantification (BLQ) were imputed as half of the lower limit of quantification value. | Baseline: 2 hours post-dose; Weeks 4-32: Pre-dose; Weeks 36-48: Any time during the visit. |
| Percent Change From Baseline in Plasmacytoid Dendritic Cell (pDC) Levels | Blood samples were collected at the visits and timepoints specified and analyzed using flow cytometry. | Baseline to Weeks 4, 12, 24, 32, 36 and 48 |
| Number of Participants Who Experienced an Anti-drug Antibody (ADA) Response | The number of participants who experienced an ADA response was defined as participants with ADA positive post-baseline only or boosted their preexisting ADA during the study. | Baseline and Weeks 4, 8, 12, 24, and 36: Pre-dose |
| Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | A TEAE was any untoward medical occurrence in a participant that was not present prior to treatment but appeared following treatment, was present at treatment initiation but worsened during treatment, or was present at the treatment initiation but resolved and then reappeared while the participant was on treatment and did not necessarily have a causal relationship with the treatment. A serious TEAE was defined as any medical occurrence that had any of the following consequences:
| Day 1 to Week 48 |
| Number of Participants Who Experienced an Adverse Event of Special Interest (AESI) | An AESI was defined as a serious or non-serious adverse event of scientific and medical interest specific to understanding the treatment and may have required close monitoring and collection of additional information by the investigator. The following were defined as AESIs:
| Day 1 to Week 48 |
| Fountain Valley |
| California |
| 92708 |
| United States |
| ForCare Clinical Research | Tampa | Florida | 33613 | United States |
| DS Research | Louisville | Kentucky | 40241 | United States |
| Progressive Clinical Research, P.A. | San Antonio | Texas | 78213 | United States |
| Dermatology Specialists of Spokane | Spokane | Washington | 99202 | United States |
| Enverus Medical Research | Surrey | British Columbia | V3V 0C6 | Canada |
| Dr Dusan Sajic Medicine Professional Corporation | Guelph | Ontario | N1L 0B7 | Canada |
| Lynderm Research Inc. | Markham | Ontario | L3P 1X3 | Canada |
| The Centre for Clinical Trials | Oakville | Ontario | L6J 7W5 | Canada |
| SKiN Centre for Dermatology | Peterborough | Ontario | K9J 5K2, | Canada |
| Innovaderm Research | Montreal | Quebec | H2X 2V1 | Canada |
| Centre de Recherche Saint-Louis (Quebec) | Québec | G1W 4R4 | Canada |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Count of Participants | Participants |
|
| Severity of Alopecia Tool (SALT) Score | The SALT score determined the degree of hair loss based on the percentage of scalp surface area involved on the top, back, and each side of the scalp for alopecia areata (AA). The Investigator determined the percent scalp hair loss in a given quadrant, multiplied this by the total scalp area delineated by that quadrant, and summed the resultant numbers for each quadrant to give the total percent scalp hair loss with a range of 0-100. | Mean | Standard Deviation | score on a scale |
|
Participants received 300 mg daxdilimab as two subcutaneous (SC) injections every 4 weeks (Q4W) for 32 weeks. Participants were followed-up until Week 48.
|
|
| Secondary | Percent Change From Baseline in SALT Score at Weeks 12, 16, 20, 28, 32, and 36 | The SALT score determined the degree of hair loss based on the percentage of scalp surface area involved on the top, back, and each side of the scalp for AA. The Investigator determined the percent scalp hair loss in a given quadrant, multiplied this by the total scalp area delineated by that quadrant, and summed the resultant numbers for each quadrant to give the total percent scalp hair loss with a range of 0-100. Higher scores indicated more severe AA symptoms. A decrease in SALT score from baseline indicated a reduction in AA symptoms. Baseline indicates last non-missing valid observation prior to the first dose of daxdilimab. | Safety Analysis Set: Included all participants who received any dose of daxdilimab. | Posted | Mean | Standard Deviation | percent change in score on a scale | Baseline to Weeks 12, 16, 20, 28, 32, and 36 |
|
|
|
| Secondary | Percentage of Participants Who Achieved a ≥ 50% Reduction in SALT Score From Baseline at Weeks 12, 16, 20, 24, 28, 32, and 36 | The SALT score determined the degree of hair loss based on the percentage of scalp surface area involved on the top, back, and each side of the scalp for AA. The Investigator determined the percent scalp hair loss in a given quadrant, multiplied this by the total scalp area delineated by that quadrant, and summed the resultant numbers for each quadrant to give the total percent scalp hair loss with a range of 0-100. Higher scores indicated more severe AA symptoms. A decrease in SALT score from baseline indicated a reduction in AA symptoms. Baseline indicates last non-missing valid observation prior to the first dose of daxdilimab. | Safety Analysis Set: Included all participants who received any dose of daxdilimab. | Posted | Number | 95% Confidence Interval | percent of participants | Baseline to Weeks 12, 16, 20, 24, 28, 32, and 36 |
|
|
|
| Secondary | Percentage of Participants Who Had an Absolute SALT Score ≤ 10 at Weeks 12, 16, 20, 24, 28, 32, and 36 | The SALT score determined the degree of hair loss based on the percentage of scalp surface area involved on the top, back, and each side of the scalp for AA. The Investigator determined the percent scalp hair loss in a given quadrant, multiplied this by the total scalp area delineated by that quadrant, and summed the resultant numbers for each quadrant to give the total percent scalp hair loss with a range of 0-100. Higher scores indicated more severe AA symptoms. Baseline indicates last non-missing valid observation prior to the first dose of daxdilimab. | Safety Analysis Set: Included all participants who received any dose of daxdilimab. | Posted | Number | 95% Confidence Interval | percent of participants | Weeks 12, 16, 20, 24, 28, 32, and 36 |
|
|
|
| Secondary | Percentage of Participants Who Had an Absolute SALT Score ≤ 20 at Weeks 12, 16, 20, 24, 28, 32, and 36 | The SALT score determined the degree of hair loss based on the percentage of scalp surface area involved on the top, back, and each side of the scalp for AA. The Investigator determined the percent scalp hair loss in a given quadrant, multiplied this by the total scalp area delineated by that quadrant, and summed the resultant numbers for each quadrant to give the total percent scalp hair loss with a range of 0-100. Higher scores indicated more severe AA symptoms. Baseline indicates last non-missing valid observation prior to the first dose of daxdilimab. | Safety Analysis Set: Included all participants who received any dose of daxdilimab. | Posted | Number | 95% Confidence Interval | percent of participants | Weeks 12, 16, 20, 24, 28, 32, and 36 |
|
|
|
| Secondary | Percentage of Participants Who Had an Absolute SALT Score ≤ 30 at Weeks 12, 16, 20, 24, 28, 32, and 36 | The SALT score determined the degree of hair loss based on the percentage of scalp surface area involved on the top, back, and each side of the scalp for AA. The Investigator determined the percent scalp hair loss in a given quadrant, multiplied this by the total scalp area delineated by that quadrant, and summed the resultant numbers for each quadrant to give the total percent scalp hair loss with a range of 0-100. Higher scores indicated more severe AA symptoms. Baseline indicates last non-missing valid observation prior to the first dose of daxdilimab. | Safety Analysis Set: Included all participants who received any dose of daxdilimab. | Posted | Number | 95% Confidence Interval | percent of participants | Weeks 12, 16, 20, 24, 28, 32, and 36 |
|
|
|
| Secondary | Percentage of Participants Who Had an Absolute SALT Score ≤ 50 at Weeks 12, 16, 20, 24, 28, 32, and 36 | The SALT score determined the degree of hair loss based on the percentage of scalp surface area involved on the top, back, and each side of the scalp for AA. The Investigator determined the percent scalp hair loss in a given quadrant, multiplied this by the total scalp area delineated by that quadrant, and summed the resultant numbers for each quadrant to give the total percent scalp hair loss with a range of 0-100. Higher scores indicated more severe AA symptoms. Baseline indicates last non-missing valid observation prior to the first dose of daxdilimab. | Safety Analysis Set: Included all participants who received any dose of daxdilimab. | Posted | Number | 95% Confidence Interval | percent of participants | Weeks 12, 16, 20, 24, 28, 32, and 36 |
|
|
|
| Secondary | Percent Change From Baseline in SALT Score at Weeks 40, 44, and 48 | The SALT score determined the degree of hair loss based on the percentage of scalp surface area involved on the top, back, and each side of the scalp for AA. The Investigator determined the percent scalp hair loss in a given quadrant, multiplied this by the total scalp area delineated by that quadrant, and summed the resultant numbers for each quadrant to give the total percent scalp hair loss with a range of 0-100. Higher scores indicated more severe AA symptoms. A decrease in SALT score from baseline indicated a reduction in AA symptoms. Baseline indicates last non-missing valid observation prior to the first dose of daxdilimab. | Safety Analysis Set: Included all participants who received any dose of daxdilimab. | Posted | Mean | Standard Deviation | percent change in score on a scale | Baseline to Weeks 40, 44, and 48 |
|
|
|
| Secondary | Percentage of Participants Who Achieved a ≥ 50% Reduction in SALT Score From Baseline at Weeks 40, 44, and 48 | The SALT score determined the degree of hair loss based on the percentage of scalp surface area involved on the top, back, and each side of the scalp for AA. The Investigator determined the percent scalp hair loss in a given quadrant, multiplied this by the total scalp area delineated by that quadrant, and summed the resultant numbers for each quadrant to give the total percent scalp hair loss with a range of 0-100. Higher scores indicated more severe AA symptoms. A decrease in SALT score from baseline indicated a reduction in AA symptoms. Baseline indicates last non-missing valid observation prior to the first dose of daxdilimab. | Safety Analysis Set: Included all participants who received any dose of daxdilimab. | Posted | Number | 95% Confidence Interval | percent of participants | Baseline to Weeks 40, 44, and 48 |
|
|
|
| Secondary | Percentage of Participants Who Had an Absolute SALT Score ≤ 10 at Weeks 40, 44 and 48 | The SALT score determined the degree of hair loss based on the percentage of scalp surface area involved on the top, back, and each side of the scalp for AA. The Investigator determined the percent scalp hair loss in a given quadrant, multiplied this by the total scalp area delineated by that quadrant, and summed the resultant numbers for each quadrant to give the total percent scalp hair loss with a range of 0-100. Higher scores indicated more severe AA symptoms. Baseline indicates last non-missing valid observation prior to the first dose of daxdilimab. | Safety Analysis Set: Included all participants who received any dose of daxdilimab. | Posted | Number | 95% Confidence Interval | percent of participants | Weeks 40, 44 and 48 |
|
|
|
| Secondary | Percentage of Participants Who Had an Absolute SALT Score ≤ 20 at Weeks 40, 44 and 48 | The SALT score determined the degree of hair loss based on the percentage of scalp surface area involved on the top, back, and each side of the scalp for AA. The Investigator determined the percent scalp hair loss in a given quadrant, multiplied this by the total scalp area delineated by that quadrant, and summed the resultant numbers for each quadrant to give the total percent scalp hair loss with a range of 0-100. Higher scores indicated more severe AA symptoms. Baseline indicates last non-missing valid observation prior to the first dose of daxdilimab. | Safety Analysis Set: Included all participants who received any dose of daxdilimab. | Posted | Number | 95% Confidence Interval | percent of participants | Weeks 40, 44 and 48 |
|
|
|
| Secondary | Percentage of Participants Who Had an Absolute SALT Score ≤ 30 at Weeks 40, 44 and 48 | The SALT score determined the degree of hair loss based on the percentage of scalp surface area involved on the top, back, and each side of the scalp for AA. The Investigator determined the percent scalp hair loss in a given quadrant, multiplied this by the total scalp area delineated by that quadrant, and summed the resultant numbers for each quadrant to give the total percent scalp hair loss with a range of 0-100. Higher scores indicated more severe AA symptoms. Baseline indicates last non-missing valid observation prior to the first dose of daxdilimab. | Safety Analysis Set: Included all participants who received any dose of daxdilimab. | Posted | Number | 95% Confidence Interval | percent of participants | Weeks 40, 44 and 48 |
|
|
|
| Secondary | Percentage of Participants Who Had an Absolute SALT Score ≤ 50 at Weeks 40, 44 and 48 | The SALT score determined the degree of hair loss based on the percentage of scalp surface area involved on the top, back, and each side of the scalp for AA. The Investigator determined the percent scalp hair loss in a given quadrant, multiplied this by the total scalp area delineated by that quadrant, and summed the resultant numbers for each quadrant to give the total percent scalp hair loss with a range of 0-100. Higher scores indicated more severe AA symptoms. Baseline indicates last non-missing valid observation prior to the first dose of daxdilimab. | Safety Analysis Set: Included all participants who received any dose of daxdilimab. | Posted | Number | 95% Confidence Interval | percent of participants | Weeks 40, 44 and 48 |
|
|
|
| Secondary | Serum Concentration of Daxdilimab | Blood samples were collected at the visits and time points specified. All post-baseline concentrations below the limit of quantification (BLQ) were imputed as half of the lower limit of quantification value. | Pharmacokinetic (PK) Analysis Set: Included all participants who received any dose of daxdilimab and had at least one measurable PK concentration post-dose. Only participants with evaluable data at each timepoint were included. | Posted | Mean | Standard Deviation | ng/mL | Baseline: 2 hours post-dose; Weeks 4-32: Pre-dose; Weeks 36-48: Any time during the visit. |
|
|
|
| Secondary | Percent Change From Baseline in Plasmacytoid Dendritic Cell (pDC) Levels | Blood samples were collected at the visits and timepoints specified and analyzed using flow cytometry. | Safety Analysis Set: Included all participants who received any dose of daxdilimab. Only participants with evaluable data at each time point were included. | Posted | Median | Full Range | percent change in pDC levels | Baseline to Weeks 4, 12, 24, 32, 36 and 48 |
|
|
|
| Secondary | Number of Participants Who Experienced an Anti-drug Antibody (ADA) Response | The number of participants who experienced an ADA response was defined as participants with ADA positive post-baseline only or boosted their preexisting ADA during the study. | Safety Analysis Set: Included all participants who received any dose of daxdilimab. | Posted | Count of Participants | Participants | Baseline and Weeks 4, 8, 12, 24, and 36: Pre-dose |
|
|
|
| Secondary | Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | A TEAE was any untoward medical occurrence in a participant that was not present prior to treatment but appeared following treatment, was present at treatment initiation but worsened during treatment, or was present at the treatment initiation but resolved and then reappeared while the participant was on treatment and did not necessarily have a causal relationship with the treatment. A serious TEAE was defined as any medical occurrence that had any of the following consequences:
| Safety Analysis Set: Included all participants who received any dose of daxdilimab. | Posted | Count of Participants | Participants | Day 1 to Week 48 |
|
|
|
| Secondary | Number of Participants Who Experienced an Adverse Event of Special Interest (AESI) | An AESI was defined as a serious or non-serious adverse event of scientific and medical interest specific to understanding the treatment and may have required close monitoring and collection of additional information by the investigator. The following were defined as AESIs:
| Safety Analysis Set: Included all participants who received any dose of daxdilimab. | Posted | Count of Participants | Participants | Day 1 to Week 48 |
|
|
|
| 0 |
| 30 |
| 0 |
| 30 |
| 17 |
| 30 |
| Diarrhoea | Gastrointestinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Fatigue | General disorders | MedDRA 24.1 | Systematic Assessment |
|
| Injection site reaction | General disorders | MedDRA 24.1 | Systematic Assessment |
|
| Seasonal allergy | Immune system disorders | MedDRA 24.1 | Systematic Assessment |
|
| COVID-19 | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
|
| Nasopharyngitis | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
|
| Upper respiratory tract infection | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
|
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA 24.1 | Systematic Assessment |
|
| Dizziness | Nervous system disorders | MedDRA 24.1 | Systematic Assessment |
|
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Pruritus | Skin and subcutaneous tissue disorders | MedDRA 24.1 | Systematic Assessment |
|
The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.
| D017437 |
| Skin and Connective Tissue Diseases |
| Title | Measurements |
|---|---|
|
| Week 28 |
|
| Week 32 |
|
| Week 36 |
|
| Title | Measurements |
|---|---|
|
| Week 24 |
|
| Week 28 |
|
| Week 32 |
|
| Week 36 |
|
| Title | Measurements |
|---|---|
|
| Week 24 |
|
| Week 28 |
|
| Week 32 |
|
| Week 36 |
|
| Title | Measurements |
|---|---|
|
| Week 24 |
|
| Week 28 |
|
| Week 32 |
|
| Week 36 |
|
| Title | Measurements |
|---|---|
|
| Week 24 |
|
| Week 28 |
|
| Week 32 |
|
| Week 36 |
|
| Title | Measurements |
|---|---|
|
| Week 24 |
|
| Week 28 |
|
| Week 32 |
|
| Week 36 |
|
| Title | Measurements |
|---|---|
|
| Title | Measurements |
|---|---|
|
| Title | Measurements |
|---|---|
|
| Title | Measurements |
|---|---|
|
| Title | Measurements |
|---|---|
|
| Title | Measurements |
|---|---|
|
|
| Week 8 |
|
|
| Week 12 |
|
|
| Week 16 |
|
|
| Week 20 |
|
|
| Week 24 |
|
|
| Week 28 |
|
|
| Week 32 |
|
|
| Week 36 |
|
|
| Week 40 |
|
|
| Week 44 |
|
|
| Week 48 |
|
|
|
| Week 24 |
|
|
| Week 32 |
|
|
| Week 36 |
|
|
| Week 48 |
|
|